Next Article in Journal
Low-Dose Nicotine Activates EGFR Signaling via α5-nAChR and Promotes Lung Adenocarcinoma Progression
Next Article in Special Issue
Label-Free Mass Spectrometry-Based Quantification of Linker Histone H1 Variants in Clinical Samples
Previous Article in Journal
Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy
Previous Article in Special Issue
Dysregulation of Key Proteins Associated with Sperm Motility and Fertility Potential in Cancer Patients
Open AccessReview

The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives

1
Department of Clinical Science, University of Bergen, 5021 Bergen, Norway
2
The Proteomics Facility of the University of Bergen (PROBE), Department of Biomedicine, University of Bergen, 5009 Bergen, Norway
3
The Department of Biomedicine, University of Bergen, 5009 Bergen, Norway
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(18), 6830; https://doi.org/10.3390/ijms21186830
Received: 28 August 2020 / Revised: 10 September 2020 / Accepted: 15 September 2020 / Published: 17 September 2020
(This article belongs to the Special Issue Recent Advances of Proteomics Applied to Cancer and Human Diseases)
With the current reproducibility of proteome preparation workflows along with the speed and sensitivity of the mass spectrometers, the transition of the mass spectrometry (MS)-based proteomics technology from biomarker discovery to clinical implementation is under appraisal in the biomedicine community. Therefore, this technology might be implemented soon to detect well-known biomarkers in cancers and other diseases. Acute myeloid leukemia (AML) is an aggressive heterogeneous malignancy that requires intensive treatment to cure the patient. Leukemia relapse is still a major challenge even for patients who have favorable genetic abnormalities. MS-based proteomics could be of great help to both describe the proteome changes of individual patients and identify biomarkers that might encourage specific treatments or clinical strategies. Herein, we will review the advances and availability of the MS-based proteomics strategies that could already be used in clinical proteomics. However, the heterogeneity of complex diseases as AML requires consensus to recognize AML biomarkers and to establish MS-based workflows that allow their unbiased identification and quantification. Although our literature review appears promising towards the utilization of MS-based proteomics in clinical AML in a near future, major efforts are required to validate AML biomarkers and agree on clinically approved workflows. View Full-Text
Keywords: acute myeloid leukemia; clinical proteomics; diagnosis; prognosis; treatment; biomarker; bioinformatics pipeline; laboratory robots acute myeloid leukemia; clinical proteomics; diagnosis; prognosis; treatment; biomarker; bioinformatics pipeline; laboratory robots
Show Figures

Figure 1

MDPI and ACS Style

Hernandez-Valladares, M.; Bruserud, Ø.; Selheim, F. The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives. Int. J. Mol. Sci. 2020, 21, 6830.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop